P76.10 Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.01.1067 ◽

2021 ◽

Vol 16 (3) ◽

pp. S589-S590

Author(s):

T. Chu ◽

W. Zhang ◽

B. Zhang ◽

R. Zhong ◽

C. Shi ◽

...

Keyword(s):

Egfr Mutations ◽

Phase 2 ◽

Small Cell Lung ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)70381-x ◽

2014 ◽

Vol 15 (11) ◽

pp. 1236-1244 ◽

Author(s):

Takashi Seto ◽

Terufumi Kato ◽

Makoto Nishio ◽

Koichi Goto ◽

Shinji Atagi ◽

...

Keyword(s):

Egfr Mutations ◽

Phase 2 ◽

Small Cell Lung ◽

Multicentre Phase ◽

First Line Therapy ◽

Line Therapy ◽

Download Full-text

9079 Pemetrexed in combination with cisplatin or carboplatin in the first line therapy of locally advanced or metastatic non-small cell lung cancer: a randomized, two-arm, parallel, open-label, multicentric phase 2 study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71792-6 ◽

2009 ◽

Vol 7 (2) ◽

pp. 528-529 ◽

Author(s):

W. Schuette ◽

A. Groeschel ◽

M. Sebastian ◽

S. Andreas ◽

T. Mueller ◽

...

Keyword(s):

Lung Cancer ◽

Locally Advanced ◽

Phase 2 ◽

Small Cell Lung ◽

First Line Therapy ◽

Line Therapy ◽

Download Full-text

Abstract C122: A randomized, multicenter, open-label, phase 2 study of paclitaxel-carboplatin (PC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus PC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

10.1158/1535-7163.targ-15-c122 ◽

2015 ◽

Author(s):

David Spigel ◽

Alexander Luft ◽

Rodryg Ramlau ◽

Mazen Khalil ◽

Joo-Hang Kim ◽

...

Keyword(s):

Stage Iv ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Study ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Abstract 4606: Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC)

10.1158/1538-7445.am2012-4606 ◽

2012 ◽

Author(s):

Alice T. Shaw ◽

Doru Ghizdavescu ◽

Minish Jain ◽

Constantin Volovat ◽

Deepa Subramaniam ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase 2 ◽

Small Cell Lung ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

P3-135: Results of an open-label, Phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab as first-line therapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000284110.26459.89 ◽

2007 ◽

Vol 2 (8) ◽

pp. S736-S737

Author(s):

Craig Reynolds ◽

David Barrera ◽

Duy Quoc Vu ◽

Robert Jotte ◽

Alexander I. Spira ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell Lung ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

Download Full-text

P-287 Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study

Annals of Oncology ◽

10.1093/annonc/mdw199.277 ◽

2016 ◽

Vol 27 ◽

pp. ii84

Author(s):

Dean Andrew ◽

Ramanathan Ramesh ◽

Belota Brooke ◽

Belanger Bruce ◽

Adib Deyaa ◽

...

Keyword(s):

Pancreatic Adenocarcinoma ◽

Phase 2 ◽

First Line Therapy ◽

Line Therapy ◽

Metastatic Pancreatic Adenocarcinoma ◽

Phase 2 Study ◽

Open Label Phase ◽

Nanoliposomal Irinotecan

Download Full-text

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

Oncology Reports ◽

10.3892/or.2012.1871 ◽

2012 ◽

Vol 28 (3) ◽

pp. 763-767 ◽

Author(s):

M. MICHAEL ◽

N. PAVLAKIS ◽

P. CLINGAN ◽

R. DE BOER ◽

M. JOHNSTON ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell Lung ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

Download Full-text

Abstract CT311: A randomized, open-label phase 2 study of efatutazone and erlotinib as second- or third-line therapy for non-small cell lung cancer (NSCLC)

10.1158/1538-7445.am2014-ct311 ◽

2014 ◽

Author(s):

Ana B. Oton ◽

Byoung Chul Cho ◽

Myung-Ju Ahn ◽

Sang-We Kim ◽

Kirushnakumar Subramanian ◽

...

Keyword(s):

Lung Cancer ◽

Phase 2 ◽

Small Cell Lung ◽

Line Therapy ◽

Phase 2 Study ◽

Open Label Phase ◽

Third Line Therapy ◽

Download Full-text

Final Results of a Phase 2, Open-Label Study of Ramucirumab (IMC-1121B; RAM), an IGG1 MAB Targeting Vegfr-2, with Paclitaxel and Carboplatin as First-Line Therapy in Patients (PTS) with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00735696)

Annals of Oncology ◽

10.1016/s0923-7534(20)33884-9 ◽

2012 ◽

Vol 23 ◽

pp. ix422-ix423

Author(s):

D.R. Camidge ◽

R.C. Doebele ◽

M. Ballas ◽

T. Jahan ◽

M. Haigentz ◽

...

Keyword(s):

Lung Cancer ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label Study ◽

Label Study ◽

First Line Therapy ◽

Download Full-text

A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdw383.98 ◽

2016 ◽

Vol 27 ◽

pp. vi454 ◽

Author(s):

M. Socinski ◽

M. Gil ◽

J. Shahidi ◽

G.Y. Chao ◽

L. Villaruz

Keyword(s):

Stage Iv ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Study ◽

Open Label Phase ◽

First Line Treatment

Download Full-text